{"a":[{"_":"Fierce Pharma Asia—Legend CEO exits; Merck’s hush-hush PD-1xVEGF plan; Otsuka’s novel ADHD nod","$":{"href":"/pharma/legend-ceo-exits-merck-hush-hush-pd-1-vegf-plan-otsuka-novel-adhd-nod","hreflang":"en"}}]}

Summary

Legend Biotech's CEO Ying Huang resigned after six years, while Otsuka received FDA approval for Simtriyo, a new ADHD therapy class. Merck posted and deleted information about a clinical trial combining its PD-1xVEGF bispecific with a TROP2 ADC.